Maia Pharms Inc Company Profile
✉ Email this page to a colleague
What is the competitive landscape for MAIA PHARMS INC, and what generic alternatives to MAIA PHARMS INC drugs are available?
MAIA PHARMS INC has nine approved drugs.
There are seven US patents protecting MAIA PHARMS INC drugs.
There are four patent family members on MAIA PHARMS INC drugs in three countries and seventy-two supplementary protection certificates in nine countries.
Drugs and US Patents for Maia Pharms Inc
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Maia Pharms Inc | LEVOTHYROXINE SODIUM | levothyroxine sodium | POWDER;INTRAVENOUS | 208749-003 | Dec 21, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Maia Pharms Inc | SINCALIDE | sincalide | POWDER;INTRAVENOUS | 210850-001 | Nov 22, 2022 | RX | Yes | Yes | 11,110,063 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-001 | Jul 27, 2022 | DISCN | Yes | No | 11,679,119 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Maia Pharms Inc | LEVOTHYROXINE SODIUM | levothyroxine sodium | POWDER;INTRAVENOUS | 208749-002 | Dec 21, 2018 | AP | RX | No | No | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Maia Pharms Inc | SINCALIDE | sincalide | POWDER;INTRAVENOUS | 210850-001 | Nov 22, 2022 | RX | Yes | Yes | 11,318,100 | ⤷ Try a Trial | Y | ⤷ Try a Trial | |||
Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-001 | Jul 27, 2022 | DISCN | Yes | No | 11,752,164 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
Maia Pharms Inc | BORTEZOMIB | bortezomib | SOLUTION;INTRAVENOUS | 215331-002 | Jul 27, 2022 | DISCN | Yes | No | 11,752,164 | ⤷ Try a Trial | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for MAIA PHARMS INC drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | for Injection | 100 mcg/vial and 500 mcg/vial | ➤ Subscribe | 2015-04-14 |
➤ Subscribe | for Injection | 200 mcg/vial | ➤ Subscribe | 2015-05-01 |
International Patents for Maia Pharms Inc Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
World Intellectual Property Organization (WIPO) | 2019040904 | ⤷ Try a Trial |
European Patent Office | 3672616 | ⤷ Try a Trial |
World Intellectual Property Organization (WIPO) | 2023049346 | ⤷ Try a Trial |
Canada | 3073944 | ⤷ Try a Trial |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Maia Pharms Inc Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0290047 | SPC/GB97/078 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MANGAFODIPIR AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR MANGAFODIPIR TRISODIUM; REGISTERED: UK EU/1/97/040/001 19970522; UK EU/1/97/040/002 19970522 |
1912999 | 2014/058 | Ireland | ⤷ Try a Trial | PRODUCT NAME: SIMEPREVIR, OR A SALT THEREOF, INCLUDING SIMEPREVIR SODIUM; REGISTRATION NO/DATE: EU/1/14/924/001-002 20140516 |
2673237 | LUC00111 | Luxembourg | ⤷ Try a Trial | PRODUCT NAME: SODIUM ZIRCONIUM CYCLOSILICATE; AUTHORISATION NUMBER AND DATE: EU/1/17/1173 20180326 |
2203431 | 2015/009 | Ireland | ⤷ Try a Trial | PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115 |
0489070 | 300162 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: BIVALIRUDINE; FIRST REGISTRATION,DATE: EU/1/04/289/001, 20040920 |
1856135 | 2020/017 | Ireland | ⤷ Try a Trial | PRODUCT NAME: FOSTAMATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, OR A HYDRATE, SOLVATE OR N-OXIDE OF FOSTAMATINIB OR THE PHARMACEUTICALLY ACCEPTABLE SALT OF FOSTAMATINIB, ESPECIALLY FOSTAMATINIB DISODIUM, OPTIONALLY IN FORM OF A HYDRATE; REGISTRATION NO/DATE: EU/1/19/1405 20200113 |
0480717 | SPC/GB98/025 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: MONTELUKAST, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREFERABLY MONTELUKAST SODIUM; REGISTERED: FI 12766 19970825; FI 12767 19970825; UK 00025/0357 19980115; UK 00025/0358 19980115 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.